Paradigm Biocapital Advisors LP 13F holdings, Q3 2024
Holdings as of September 30, 2024 · filings on SEC EDGAR · latest filing →
Paradigm Biocapital Advisors LP disclosed 31 US equity positions worth $2.9bn in its Q3 2024 13F filing. The largest position was NUVALENT INC at 17.9% of the reported book, followed by ACLXGBX and ARGX.
What did Paradigm Biocapital Advisors LP own in Q3 2024? Top 31 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs prior |
|---|---|---|---|---|---|---|---|
| 1 | NUVALENT INC | 17.9% | $511.5m | 5,000,000 | – | ||
| 2 | ACLXGBX ARCELLX INC | 11.7% | $334.0m | 4,000,000 | – | ||
| 3 | ARGX ARGENX SE | Healthcare | 9.1% | $260.4m | 480,374 | – | |
| 4 | RVMD REVOLUTION MEDICINES INC | Healthcare | 8.4% | $241.0m | 5,314,089 | – | |
| 5 | CRNXGBP CRINETICS PHARMACEUTICALS IN | 4.5% | $128.6m | 2,516,686 | – | ||
| 6 | MERUS N V | 4.3% | $122.6m | 2,454,917 | – | ||
| 7 | JANX JANUX THERAPEUTICS INC | Healthcare | 3.8% | $109.1m | 2,400,574 | – | |
| 8 | KURA KURA ONCOLOGY INC | Healthcare | 3.0% | $84.6m | 4,331,321 | – | |
| 9 | TARS TARSUS PHARMACEUTICALS INC | Healthcare | 2.8% | $80.3m | 2,440,445 | – | |
| 10 | EWTX EDGEWISE THERAPEUTICS INC | 2.6% | $74.4m | 2,789,172 | – | ||
| 11 | IRON DISC MEDICINE INC | Healthcare | 2.6% | $73.6m | 1,497,720 | – | |
| 12 | PCVX VAXCYTE INC | Healthcare | 2.5% | $71.7m | 627,732 | – | |
| 13 | VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 2.3% | $65.9m | 2,895,689 | – | |
| 14 | OLMA OLEMA PHARMACEUTICALS INC | Healthcare | 2.3% | $65.7m | 5,503,600 | – | |
| 15 | ARVN ARVINAS INC | Healthcare | 2.0% | $57.6m | 2,339,961 | – | |
| 16 | YMABUSD Y-MABS THERAPEUTICS INC | 1.9% | $53.7m | 4,086,346 | – | ||
| 17 | COGT COGENT BIOSCIENCES INC | Healthcare | 1.7% | $49.8m | 4,609,762 | – | |
| 18 | VERA VERA THERAPEUTICS INC | Healthcare | 1.7% | $48.5m | 1,096,851 | – | |
| 19 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | 1.6% | $47.0m | 931,480 | – | |
| 20 | ONC BEIGENE LTD | Healthcare | 1.6% | $45.0m | 200,336 | – | |
| 21 | IMTX IMMATICS N.V | Healthcare | 1.6% | $44.6m | 3,904,862 | – | |
| 22 | APGE APOGEE THERAPEUTICS INC | Healthcare | 1.4% | $41.2m | 701,817 | – | |
| 23 | IMVT IMMUNOVANT INC | Healthcare | 1.4% | $38.9m | 1,362,827 | – | |
| 24 | CGEM CULLINAN THERAPEUTICS INC | Healthcare | 1.4% | $38.9m | 2,321,013 | – | |
| 25 | SYRE SPYRE THERAPEUTICS INC | 1.3% | $37.3m | 1,267,581 | – | ||
| 26 | PLRX PLIANT THERAPEUTICS INC | Healthcare | 1.2% | $34.8m | 3,104,486 | – | |
| 27 | KROS KEROS THERAPEUTICS INC | Healthcare | 1.1% | $30.5m | 525,037 | – | |
| 28 | ERAS ERASCA INC | Healthcare | 1.0% | $29.1m | 10,668,141 | – | |
| 29 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 0.6% | $17.6m | 719,660 | – | |
| 30 | CATX PERSPECTIVE THERAPEUTICS INC | 0.4% | $12.3m | 919,692 | – | ||
| 31 | CMPS COMPASS PATHWAYS PLC | Healthcare | 0.3% | $7.3m | 1,160,000 | – |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.